Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders

Programme Category

EU Competitive Programmes

Programme Name

Horizon Europe (2021-2027)

Programme Description

Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.

Programme Details

Identifier Code

HORIZON-HLTH-2024-DISEASE-03-13-two-stage

Call

Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders

Summary

Treatments for some high-burden brain disorders are potentially on the horizon. For some disorders, a definitive diagnosis is difficult, expensive and time-consuming. Simple blood or other fluid-derived (e.g. saliva, urine, sweat) tests for markers that may indicate early signs of the disorder, and which can be deployed for widespread clinical use are needed. The brain disorders within the scope of this topic fall under two categories, namely those listed under chapters six and eight of the International Classification of Diseases. Proposals in the area of mental disorders are encouraged.

Detailed Call Description

Proposals should address all of the following aspects:

Proposals should aim to validate biomarkers that can reliably confirm early stages of the human brain disorder and guide treatment/ intervention selection.
Proposals should aim to provide evidence supporting the regulatory acceptance of the biomarkers.
Exploitation of existing data, biobanks, registries and cohorts is expected, together with the generation of new key data.
Inclusion of patients or patient organisations in the research is strongly encouraged, as to ensure that their views are considered.
Sex and gender aspects, age, socio-economic, lifestyle and behavioural factors should be taken into consideration in the study.
To enable sharing of samples, quality data and advanced analytical and digital tools, consideration should be made for using infrastructures already developed at the European or national level.
To enable the management of brain disorders, consideration should be made in demonstrating the gained cost efficiency.

Applicants invited to the second stage and envisaging to include clinical studies should provide details of their clinical studies in the dedicated annex using the template provided in the submission system.

Call Total Budget

€25.00 million

Financing percentage by EU or other bodies / Level of Subsidy or Loan

100%

EU contribution per project: €6.00 and €8.00 million

Thematic Categories

Health
Research, Technological Development and Innovation

Eligibility for Participation

Associations
Central Government
Large Enterprises
Legal Entities
NGOs
Non Profit Organisations
Private Bodies
Researchers/Research Centers/Institutions
Semi-governmental organisations
Small and Medium Enterprises (SMEs)
State-owned Enterprises

Eligibility For Participation Notes

SME participation is encouraged.

In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.

Call Opening Date

26/04/2023

Call Closing Date

19/09/2023

National Contact Point(s)

Research and Innovation Foundation
29a Andrea Michalakopoulou, 1075 Nicosia,
P.B. 23422, 1683 Nicosia
Telephone: +357 22205000
Fax: +357 22205001
Email: support@research.org.cy
Website: https://www.research.org.cy/en/

Contact Persons:
George Christou
Scientific Officer
Email: gchristou@research.org.cy

Ioannis Theodorou
Scientific Officer
Telephone: +357 22 205 038
Email: itheodorou@research.org.cy

(Publish Date: 07/04/2023-for internal use only)

EU Contact Point

European Commission, Directorate-General for Research and Innovation

https://ec.europa.eu/info/departments/research-and-innovation_en#contact